EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia

Nina Kim iD, E Dianne Pulte, Lori A Ehrlich iD, Alexei C Ionan iD, Spencer Haupert iD, Jonathon Vallejo iD, Francis Green, Nan Zheng, Yun Wang, Jiang Liu, Javier G Blanco, Sarah E Dorff iD und 8 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-25-01369 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Nina Kim und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Hauptthemen laut MEDLINE: Anemia, Myelodysplastic Syndromes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On June 6, 2024, the US Food and Drug Administration (FDA) approved imetelstat (RYTELO, Geron) for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring ≥4 red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents. The approval was based on a randomized (2:1), double-blind, placebo-controlled multicenter trial, Study MDS3001. In the protocol-specified primary analysis, the ≥8-week RBC transfusion independence (RBC-TI) rate was 39.8% (95% CI, 30.9 to 49.3) in the imetelstat group versus 15% (95% CI, 7.1 to 26.6) in the placebo group ( P < .001). This was supported by the rate of ≥24-week RBC-TI of 28% (95% CI, 20.1 to 37) in the imetelstat group versus 3.3% (95% CI, 0.4 to 11.5) in the placebo group ( P < .001). However, there was no major difference between arms regarding the key secondary end point of erythroid response (HI-E) per International Working Group 2006 criteria or secondary end points reflective of a disease-modifying effect such as complete remission rate and overall survival. The most common adverse reactions were thrombocytopenia, leukopenia, neutropenia, increased liver enzymes, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19, and headache. The rate of grade 3 to 4 neutropenia and thrombocytopenia were 72% and 65%, respectively, in the imetelstat arm compared with 7% and 8% in the placebo arm. Despite the high incidence of neutropenia and thrombocytopenia, the FDA determined that the benefits outweighed the risks in this patient population with high unmet need. Postmarketing requirements were issued to evaluate long-term safety and to conduct a randomized trial comparing at least two dosages of imetelstat to potentially minimize risks of imetelstat treatment and improve tolerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaMyelodysplastic SyndromesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDouble-Blind MethodDrug ApprovalErythrocyte TransfusionOligonucleotidesUnited StatesUnited States Food and Drug Administration

Substanzen

imetelstatOligonucleotides

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
  • Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD.

ORCID-Profile: Nina Kim, Lori A Ehrlich, Alexei C Ionan, Spencer Haupert, Jonathon Vallejo, Sarah E Dorff, Moran Choe, Vishal Bhatnagar, Marc Theoret, Richard Pazdur, R Angelo De Claro, Kelly J Norsworthy

Förderung

  • Intramural FDA HHS

Zitieren

APA

Kim, N., Pulte, E. D., Ehrlich, L. A., Ionan, A. C., Haupert, S., Vallejo, J., Green, F., Zheng, N., Wang, Y., Liu, J., Blanco, J. G., Dorff, S. E., Booth, B., Choe, M., Gehrke, B., Bhatnagar, V., Theoret, M., Pazdur, R., De Claro, R. A., & Norsworthy, K. J. (2025). US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01369

Vancouver

Kim N, Pulte ED, Ehrlich LA, Ionan AC, Haupert S, Vallejo J, et al. US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-01369

BibTeX
@article{Kim2025,
  author = {Kim, Nina and Pulte, E Dianne and Ehrlich, Lori A and Ionan, Alexei C and Haupert, Spencer and Vallejo, Jonathon and Green, Francis and Zheng, Nan and Wang, Yun and Liu, Jiang and Blanco, Javier G and Dorff, Sarah E and Booth, Brian and Choe, Moran and Gehrke, Brenda and Bhatnagar, Vishal and Theoret, Marc and Pazdur, Richard and De Claro, R Angelo and Norsworthy, Kelly J},
  title = {US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-25-01369}
}
Kostenlos starten →